Konishi T, et al. - Researchers evaluated induction modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus bevacizumab followed by S− 1-based chemoradiotherapy in magnetic resonance imaging (MRI)-defined poor-risk locally advanced low rectal cancer in terms of safety and effectiveness by performing this prospective phase 2 trial with 43 patients. MRI-defined poor-risk features included circumferential resection margin (CRM) ≤ 1 mm, cT4, positive lateral nodes, mesorectal N2 disease, and/or requiring abdominoperineal resection. Patients received six cycles of mFOLFOX6 with 5 mg/kg bevacizumab followed by oral S-1 (80 mg/m2/day on days 1–14 and 22–35) plus radiotherapy (50.4 Gy). In poor-risk locally advanced low rectal cancer, a high pathological complete response (pCR) rate was achieved with satisfactory toxicity and postoperative complications.